Actively Recruiting
Expression of Stress Markers During Meth Treatment (EXPRESS+)
Led by University of California, Los Angeles · Updated on 2024-05-07
55
Participants Needed
1
Research Sites
186 weeks
Total Duration
On this page
Sponsors
U
University of California, Los Angeles
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.
CONDITIONS
Official Title
Expression of Stress Markers During Meth Treatment (EXPRESS+)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Assigned male sex at birth
- Aged 18 to 45 years
- Reports having sex with men in the past 12 months
- HIV-positive (confirmed by certification or rapid test)
- Has an HIV care provider seen in the past 12 months
- Has a current antiretroviral prescription
- For methamphetamine use disorder group: meets DSM-5 criteria for methamphetamine use disorder using SCID-5
- For methamphetamine use disorder group: urine test positive for methamphetamine within 30 days of screening
- For methamphetamine use disorder group: seeking treatment for methamphetamine use disorder
- For methamphetamine use disorder group: able to attend twice weekly appointments for drug testing and treatment
You will not qualify if you...
- Identifies as (cis- or transgender) female
- For methamphetamine use disorder group: reports another current or past substance use disorder
- For methamphetamine use disorder group: currently in another intervention or clinical trial for substance use
- For methamphetamine use disorder group: positive test for opioids, cocaine, and/or MDMA
- For control group: positive test for methamphetamine, opioids, cocaine, and/or MDMA
- For control group: reports substance use (methamphetamine, opioids, cocaine, MDMA, hallucinogens, heavy alcohol use, and/or tobacco) in the past 6 months
- For control group: reports past or current substance use disorder
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCLA Vine Street Clinic
Los Angeles, California, United States, 90038
Actively Recruiting
Research Team
M
Michael J Li, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here